Nykode Therapeutics AS (OSL:NYKD)
Norway · Delayed Price · Currency is NOK 3.380
+0.030 (0.90%)
Aug 4, 2026, 4:27 PM CET
Nykode Therapeutics AS Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 60.29 | 115.4 | 162.6 | 206.39 | 216.23 |
Short-Term Investments | - | - | - | - | 12.17 |
Cash & Short-Term Investments | 60.29 | 115.4 | 162.6 | 206.39 | 228.4 |
Cash Growth | -47.76% | -29.03% | -21.21% | -9.64% | 9.39% |
Accounts Receivable | - | - | - | 2.54 | 23.75 |
Other Receivables | 1.6 | 1.67 | 3.07 | 2.94 | 3.71 |
Total Trade Receivables | 1.6 | 1.67 | 3.07 | 5.49 | 27.46 |
Total Current Assets | 61.89 | 117.07 | 165.68 | 211.87 | 255.86 |
Net Property, Plant & Equipment | 5.68 | 7.74 | 10.52 | 9.53 | 9.17 |
Other Intangible Assets | 0.07 | 0.07 | 0.07 | 0.03 | 0.03 |
Other Long-Term Assets | 32.22 | 28.6 | 31.92 | 0.05 | 0.5 |
Total Assets | 99.96 | 153.48 | 208.19 | 221.48 | 265.56 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.07 | 3.68 | 7.06 | 10.18 | 8.49 |
Current Portion of Leases | 1.25 | 1.29 | 1.46 | 1.15 | 1.35 |
Unearned Revenue | - | - | 8.23 | 19.74 | 16.04 |
Other Current Liabilities | 0.87 | 4.13 | 3.85 | 7.93 | 5.48 |
Total Current Liabilities | 6.19 | 9.1 | 20.61 | 38.99 | 31.37 |
Long-Term Leases | 1.3 | 2.15 | 4.27 | 4.37 | 5.82 |
Other Long-Term Liabilities | 0.93 | 6.02 | 12.05 | 21.11 | 34.32 |
Total Long-Term Liabilities | 2.23 | 8.17 | 16.32 | 25.47 | 40.13 |
Total Liabilities | 8.42 | 17.27 | 36.93 | 64.46 | 71.5 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.37 | 0.37 | 0.37 | 0.34 | 0.33 |
Additional Paid-in Capital | 96.71 | 128.99 | 128.99 | 83.32 | 81.53 |
Accumulated Other Comprehensive Income | 15.65 | 15.62 | 12.35 | 8.65 | 4.74 |
Retained Earnings | -21.18 | -8.76 | 29.56 | 64.71 | 107.46 |
Shareholders' Equity | 91.54 | 136.21 | 171.26 | 157.02 | 194.06 |
Total Liabilities & Equity | 99.96 | 153.48 | 208.19 | 221.48 | 265.56 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2.55 | 3.44 | 5.73 | 5.51 | 7.17 |
Net Cash (Debt) | 57.74 | 111.96 | 156.88 | 200.87 | 221.23 |
Net Cash Growth | -48.43% | -28.63% | -21.90% | -9.20% | 6.10% |
Net Cash Per Share | 0.18 | 0.34 | 0.52 | 0.69 | 0.77 |
Book Value | 91.54 | 136.21 | 171.26 | 157.02 | 194.06 |
Book Value Per Share | 0.28 | 0.42 | 0.57 | 0.54 | 0.68 |
Tangible Book Value | 91.47 | 136.14 | 171.19 | 156.99 | 194.02 |
Tangible Book Value Per Share | 0.28 | 0.42 | 0.57 | 0.54 | 0.68 |